Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
Cibil Report
Get cibil report
My Account
Log In
Log into your account
Offers
Check out pre-approved offers now!
Languages
Chosen Language: English
Do Not Call
Do not call
En
Zenith Drugs Ltd. Share Price
N/A
1D
1M
3M
6M
1Y
5Y
Day's Range
Low
₹0.00
High
₹0.00
Price Summary
| Previous Close | ₹39.00 |
|---|---|
| Day's Range | ₹0.00 - ₹0.00 |
| Open | ₹0.00 |
| 52 Week Range | ₹33.30 - ₹63.60 |
| Volume | 0 |
| Market Cap | ₹0.00 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | |
|---|---|
| Market Cap (₹ in Mn) | 0.00 |
| Dividend Yield(%) | 0.00 |
| Price/Earning (TTM) | 6.97 |
| TTM EPS (₹) | 5.59 |
| P/E Ratio | 11.21 |
| Book Value(₹) | 1.07 |
| PAT Margin (%) | 6.42 |
| Face Value (₹) | 10.00 |
| ROCE(%) | 25.15 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 1333.2 | 1333.2 |
| Expenses | N/A | N/A |
| PBT | 92.61 | 92.61 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 71.61 | 71.61 |
About Zenith Drugs Ltd.
| Founded | 2000 |
|---|---|
| Managing Director | Sandeep Bhardwaj |
| NSE Symbol | ZENITHDRUG |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,37,962.61 | 1,822.35 | 1,583.70 - 1,583.70 |
| Divi's Laboratories Ltd. | 2,69,450.61 | 10,096.05 | 5,647.50 - 5,647.50 |
| Torrent Pharmaceuticals Ltd. | 1,79,455.65 | 4,708.80 | 3,532.60 - 3,532.60 |
| Laurus Labs Ltd. | 1,26,703.22 | 2,322.40 | 917.95 - 917.95 |
| Lenskart Solutions Ltd. | 1,24,984.87 | 716.10 | 0.00 - 0.00 |
| Apollo Hospitals Enterprise Ltd. | 1,20,190.31 | 8,364.00 | 6,696.50 - 6,696.50 |
| Zydus Lifesciences Ltd. | 1,19,341.36 | 1,191.80 | 835.50 - 835.50 |
| Dr. Reddy's Laboratories Ltd. | 1,13,663.75 | 1,363.00 | 1,101.00 - 1,101.00 |
| Cipla Ltd. | 1,13,245.71 | 1,386.95 | 1,165.70 - 1,165.70 |
| Mankind Pharma Ltd. | 1,03,880.84 | 2,501.35 | 1,909.70 - 1,909.70 |
No Records Found
Latest News
Nov
6
2026
Posted on Nov 6th 2026
Fredun Pharma - Quaterly Results
An increase of about 84.21% to Rs. 2676.35 millions in the topline was observed for the quarter ended September 2026. The topline stood at Rs. 1452.91 millions during the similar quarter previous year.The Profit for the quarter ended September 2026 of Rs. 188.26 millions grew by 93.46% from Rs. 97.31 millions.Operating profit for the quarter ended September 2026 rose to 426.02 millions as compared to 223.34 millions of corresponding quarter ended September 2025.
| (Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202609 | 202509 | % Var | 202609 | 202509 | % Var | 202603 | 202503 | % Var | |
| Sales | 2676.35 | 1452.91 | 84.21 | 4958.83 | 2651.46 | 87.02 | 6391.21 | 4562.68 | 40.08 |
| Other Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| PBIDT | 426.02 | 223.34 | 90.75 | 753.78 | 393.25 | 91.68 | 947.94 | 550.97 | 72.05 |
| Interest | 87.76 | 77.31 | 13.52 | 173.94 | 142.63 | 21.95 | 392.98 | 223.77 | 75.62 |
| PBDT | 338.26 | 146.03 | 131.64 | 579.84 | 250.62 | 131.36 | 554.96 | 327.20 | 69.61 |
| Depreciation | 39.23 | 15.98 | 145.49 | 74.94 | 30.17 | 148.39 | 79.14 | 44.49 | 77.88 |
| PBT | 299.03 | 130.05 | 129.93 | 504.90 | 220.45 | 129.03 | 475.82 | 282.71 | 68.31 |
| TAX | 110.77 | 32.74 | 238.33 | 184.97 | 55.49 | 233.34 | 143.75 | 74.63 | 92.62 |
| Deferred Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| PAT | 188.26 | 97.31 | 93.46 | 319.93 | 164.96 | 93.94 | 332.07 | 208.08 | 59.59 |
| Equity | 169.00 | 141.65 | 19.31 | 169.00 | 141.65 | 19.31 | 54.73 | 47.22 | 15.90 |
| PBIDTM(%) | 15.92 | 15.37 | 3.55 | 15.20 | 14.83 | 2.49 | 14.83 | 12.08 | 22.83 |
Read More
Nov
6
2026
Posted on Nov 6th 2026
Shilpa Medicare - Quaterly Results
The turnover zoomed to Rs. 2061.40 millions, up 52.02% for the September 2026 quarter as against Rs. 1356.00 millions during the year-ago period.Net profit for the quarter ended September 2026 increased significantly by 71.70% to Rs. 501.20 millions from Rs. 291.90 millions.OP of the company witnessed a marginal growth to 835.20 millions from 539.40 millions in the same quarter last year.
| (Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202609 | 202509 | % Var | 202609 | 202509 | % Var | 202603 | 202503 | % Var | |
| Sales | 2061.40 | 1356.00 | 52.02 | 3951.80 | 2290.60 | 72.52 | 5970.30 | 4774.10 | 25.06 |
| Other Income | 145.70 | 120.00 | 21.42 | 241.30 | 250.20 | -3.56 | 381.40 | 696.70 | -45.26 |
| PBIDT | 835.20 | 539.40 | 54.84 | 1490.90 | 868.00 | 71.76 | 1938.60 | 2058.00 | -5.80 |
| Interest | 22.00 | 24.40 | -9.84 | 47.30 | 46.70 | 1.28 | 100.40 | 58.70 | 71.04 |
| PBDT | 822.00 | 499.30 | 64.63 | 1487.50 | 753.80 | 97.33 | 2032.40 | 1541.90 | 31.81 |
| Depreciation | 154.60 | 136.10 | 13.59 | 309.50 | 266.70 | 16.05 | 551.10 | 488.60 | 12.79 |
| PBT | 667.40 | 363.20 | 83.76 | 1178.00 | 487.10 | 141.84 | 1481.30 | 1053.30 | 40.63 |
| TAX | 166.20 | 71.30 | 133.10 | 27.60 | 8.10 | 240.74 | 151.60 | 374.40 | -59.51 |
| Deferred Tax | 9.50 | 0.90 | 955.56 | -266.90 | 45.10 | -691.80 | 76.60 | -96.40 | -179.46 |
| PAT | 501.20 | 291.90 | 71.70 | 1150.40 | 479.00 | 140.17 | 1329.70 | 678.90 | 95.86 |
| Equity | 195.60 | 97.80 | 100.00 | 195.60 | 97.80 | 100.00 | 195.60 | 97.80 | 100.00 |
| PBIDTM(%) | 40.52 | 39.78 | 1.85 | 37.73 | 37.89 | -0.44 | 32.47 | 43.11 | -24.68 |
Read More
Nov
6
2026
Posted on Nov 6th 2026
Poly Medicure - Quaterly Results
The Revenue for the quarter ended September 2026 of Rs. 4882.76 millions grew by 17.22 % from Rs. 4165.42 millions.Net profit showed a marginal rise at Rs. 920.25 millions for the quarter ended September 2026, as compared to corresponding quarter of last year.Operating profit for the quarter ended September 2026 rose to 1543.31 millions as compared to 1450.54 millions of corresponding quarter ended September 2025.
| (Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202609 | 202509 | % Var | 202609 | 202509 | % Var | 202603 | 202503 | % Var | |
| Sales | 4882.76 | 4165.42 | 17.22 | 9193.76 | 8005.89 | 14.84 | 16624.65 | 16018.00 | 3.79 |
| Other Income | 204.37 | 337.21 | -39.39 | 490.87 | 748.17 | -34.39 | 1199.18 | 897.72 | 33.58 |
| PBIDT | 1543.31 | 1450.54 | 6.40 | 3038.26 | 2878.87 | 5.54 | 5660.26 | 5356.83 | 5.66 |
| Interest | 39.97 | 27.84 | 43.57 | 83.82 | 55.98 | 49.73 | 134.33 | 114.07 | 17.76 |
| PBDT | 1503.34 | 1422.70 | 5.67 | 2954.44 | 2822.89 | 4.66 | 5457.89 | 5242.76 | 4.10 |
| Depreciation | 272.59 | 242.64 | 12.34 | 537.29 | 472.19 | 13.79 | 978.98 | 813.85 | 20.29 |
| PBT | 1230.75 | 1180.06 | 4.30 | 2417.15 | 2350.70 | 2.83 | 4478.91 | 4428.91 | 1.13 |
| TAX | 310.50 | 289.56 | 7.23 | 615.66 | 580.91 | 5.98 | 1119.06 | 1115.56 | 0.31 |
| Deferred Tax | 36.54 | 24.38 | 49.88 | 90.93 | 102.63 | -11.40 | 150.28 | 185.53 | -19.00 |
| PAT | 920.25 | 890.50 | 3.34 | 1801.49 | 1769.79 | 1.79 | 3359.85 | 3313.35 | 1.40 |
| Equity | 506.81 | 506.80 | 0.00 | 506.81 | 506.80 | 0.00 | 506.80 | 506.63 | 0.03 |
| PBIDTM(%) | 31.61 | 34.82 | -9.24 | 33.05 | 35.96 | -8.10 | 34.05 | 33.44 | 1.81 |
Read More
Nov
6
2026
Posted on Nov 6th 2026
Mercury Laboratories - Quaterly Results
The revenue for the September 2026 quarter is pegged at Rs. 190.09 millions against Rs. 190.09 millions recorded during the year-ago period.Net profit of the cmpany stood at Rs. 6.73 millions for the quarter ended September 2026 a decline of -59.06% from Rs. 16.44 millions in the same quarter last year.The Operating Profit of the company witnessed a decrease to 18.15 millions from 29.19 millions.
| (Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202609 | 202509 | % Var | 202609 | 202509 | % Var | 202603 | 202503 | % Var | |
| Sales | 190.09 | 190.09 | 0.00 | 349.72 | 371.44 | -5.85 | 759.37 | 751.01 | 1.11 |
| Other Income | 3.78 | 7.91 | -52.21 | 4.30 | 9.72 | -55.76 | 19.55 | 10.69 | 82.88 |
| PBIDT | 18.15 | 29.19 | -37.82 | 30.59 | 54.54 | -43.91 | 109.96 | 80.85 | 36.00 |
| Interest | 1.62 | 1.32 | 22.73 | 2.85 | 2.77 | 2.89 | 5.45 | 5.48 | -0.55 |
| PBDT | 16.53 | 27.87 | -40.69 | 27.74 | 51.77 | -46.42 | 100.56 | 75.37 | 33.42 |
| Depreciation | 7.37 | 8.63 | -14.60 | 14.66 | 17.06 | -14.07 | 34.20 | 28.76 | 18.92 |
| PBT | 9.16 | 19.24 | -52.39 | 13.08 | 34.71 | -62.32 | 66.36 | 46.61 | 42.37 |
| TAX | 2.43 | 2.80 | -13.21 | 3.37 | 8.60 | -60.81 | 18.03 | 15.16 | 18.93 |
| Deferred Tax | 0.13 | -2.90 | -104.48 | -0.23 | -1.90 | -87.89 | 1.42 | 1.68 | -15.48 |
| PAT | 6.73 | 16.44 | -59.06 | 9.71 | 26.11 | -62.81 | 48.33 | 31.45 | 53.67 |
| Equity | 12.00 | 12.00 | 0.00 | 12.00 | 12.00 | 0.00 | 12.00 | 12.00 | 0.00 |
| PBIDTM(%) | 9.55 | 15.36 | -37.82 | 8.75 | 14.68 | -40.43 | 14.48 | 10.77 | 34.51 |
Read More
Nov
6
2026
Posted on Nov 6th 2026
Ipca Laboratories - Quaterly Results
The Revenue for the quarter ended September 2026 of Rs. 22556.10 millions grew by 16.85 % from Rs. 19303.20 millions.A comparatively good net profit growth of 27.09% to Rs. 3872.90 millions was reported for the quarter ended September 2026 compared to Rs. 3047.40 millions of previous same quarter.Operating Profit saw a handsome growth to 6159.80 millions from 4866.30 millions in the quarter ended September 2026.
| (Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202609 | 202509 | % Var | 202609 | 202509 | % Var | 202603 | 202503 | % Var | |
| Sales | 22556.10 | 19303.20 | 16.85 | 43748.50 | 36772.20 | 18.97 | 73367.50 | 66779.20 | 9.87 |
| Other Income | 189.20 | 219.20 | -13.69 | 363.40 | 469.40 | -22.58 | 946.40 | 712.90 | 32.75 |
| PBIDT | 6159.80 | 4866.30 | 26.58 | 12110.40 | 9185.70 | 31.84 | 18749.30 | 15963.20 | 17.45 |
| Interest | 46.80 | 114.60 | -59.16 | 97.20 | 235.20 | -58.67 | 435.10 | 630.40 | -30.98 |
| PBDT | 6113.00 | 4751.70 | 28.65 | 12013.20 | 8950.50 | 34.22 | 18010.00 | 12517.40 | 43.88 |
| Depreciation | 775.90 | 668.60 | 16.05 | 1522.00 | 1299.90 | 17.09 | 2688.70 | 2519.70 | 6.71 |
| PBT | 5337.10 | 4083.10 | 30.71 | 10491.20 | 7650.60 | 37.13 | 15321.30 | 9997.70 | 53.25 |
| TAX | 1464.20 | 1035.70 | 41.37 | 2885.40 | 1982.80 | 45.52 | 3996.10 | 3490.10 | 14.50 |
| Deferred Tax | 50.00 | -9.50 | -626.32 | 170.00 | 11.00 | 1445.45 | -25.10 | 81.10 | -130.95 |
| PAT | 3872.90 | 3047.40 | 27.09 | 7605.80 | 5667.80 | 34.19 | 11325.20 | 6507.60 | 74.03 |
| Equity | 253.70 | 253.70 | 0.00 | 253.70 | 253.70 | 0.00 | 253.70 | 253.70 | 0.00 |
| PBIDTM(%) | 27.31 | 25.21 | 8.33 | 27.68 | 24.98 | 10.82 | 25.56 | 23.90 | 6.91 |
Read More
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Zenith Drugs Ltd. is ₹39.00 as of 2026-11-06.
The market capitalisation of Zenith Drugs Ltd. is ₹66.88 as of 2026-11-05.
The 1-year return of Zenith Drugs Ltd. is -22.40% as of 2026-11-06.
The P/E ratio of Zenith Drugs Ltd. is 15.31 as of 2026-11-06.
The 52-week high and low of Zenith Drugs Ltd. are ₹63.60 and ₹33.30, respectively, as of 2026-11-06.
View More
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
Home
Shopping
Loan Offers
My Accounts
Explore
